Rhys Evans Mark 25 Years Since Landmark Gene Therapy Trial
Twenty-five years after becoming the first patient to undergo a pioneering gene therapy trial, 26-year-old Rhys Evans looks back at a procedure that dismantled the prospect of a lifetime spent inside a protective bubble. Born without a functioning immune system in Nelson, Caerphilly county, Evans faced x-linked severe combined immunodeficiency (XSCID), a rare disorder affecting an estimated one in every 40,000 babies in England, according to Great Ormond Street.
Back in 2001, standard medical interventions offered only chemotherapy or an arduous bone marrow transplant. Instead, a team led by Professor Adrian Thrasher at University College London and Great Ormond Street Hospital deployed a novel experimental approach. Researchers extracted 100ml of bone marrow from Evans, inserted a corrected copy of the gene, and re-injected the modified marrow back into his body.
Thrasher noted that laboratory work on the therapy spanned 15 to 20 years before clinicians felt ready to move to human trials with Evans as the initial recipient. The patient’s own bone marrow successfully regenerated a functional immune system, allowing Evans to survive a flu infection shortly after his second birthday as an early proof of concept.
Life Outside the Isolation Chamber and Subsequent Infections
Before the intervention, Evans spent his early childhood isolated in a filtered room where visitors underwent sterilization procedures, comparing the experience to living in prison. The successful gene insertion provided resilience strong enough to later overcome Covid twice, alongside normal schooling, university, and employment as stage crew at Butlin’s in Minehead, Somerset.
The historical context of XSCID includes high-profile cases such as David Vetter, the US patient nicknamed “Bubble Boy” born in 1971 who spent his life inside isolation chambers and specialized suits before dying at age 12 following a failed transplant. Unlike Vetter’s generation, more than 130 patients have received the Great Ormond Street treatment since 2001, expanding beyond XSCID to address leukaemia, spinal muscular atrophy, and Leber’s Congenital Amaurosis.
Questions About the XSCID Treatment Protocol
What exact procedure was used on Rhys Evans in 2001?
Clinicians extracted 100ml of his bone marrow, introduced a healthy gene into the cells in a laboratory setting, and then injected the modified marrow back into his body to regenerate his immune system.
How many patients have received this gene therapy since the trial began?
More than 130 individuals have undergone the specialized treatment at Great Ormond Street Hospital since 2001, according to Professor Adrian Thrasher.
What other medical conditions are now targeted with similar gene therapy trials?
Children’s hospital trials have expanded to treat conditions including leukaemia, spinal muscular atrophy, and Leber’s Congenital Amaurosis, an inherited disorder causing blindness.